IMMUNOREACTIVITY, IMMUNOSUPPRESSION, AND CEREBRAL VASOSPASM FOLLOWING SAH

被引：0
|
作者：
PETERSON, JW [1 ]
KWUN, BD [1 ]
NISHIZAWA, S [1 ]
HACKETT, JD [1 ]
ZERVAS, NT [1 ]
机构：
[1] MASSACHUSETTS GEN HOSP,BOSTON,MA 02114
来源：
STROKE | 1988年 / 19卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：132 / 132
页数：1
相关论文
共 50 条
  • [1] Endovascular treatment of cerebral vasospasm following SAH
    Barreau, X
    Pastore, M
    Piotin, M
    Spelle, C
    Moret, J
    CEREBRAL VASOSPASM, 2001, 77 : 177 - 180
  • [2] Cerebral vasospasm following SAH: Historical perspectives
    Dumont, AS
    Kassell, NF
    Laws, ER
    JOURNAL OF NEUROSURGERY, 2004, 100 (04) : 803 - 803
  • [3] Molecular mechanisms of cerebral vasospasm following aneurysmal SAH
    Rothoerl, Ralf Dirk
    Ringel, Florian
    NEUROLOGICAL RESEARCH, 2007, 29 (07) : 636 - 642
  • [4] Vasospasm Following SAH, Pathogenesis and Treatment
    Ohkuma, Hiroki
    CEREBROVASCULAR DISEASES, 2012, 34 : 11 - 12
  • [5] Barbiturate coma for vasospasm following SAH
    Venn R.
    Critical Care, 1 (1):
  • [6] Neuromodulation for Post-SAH Cerebral Vasospasm
    Slavin, Konstantin V.
    Vannemreddy, Prasad
    NEUROMODULATION, 2022, 25 (08): : 1444 - 1445
  • [7] EFFECT OF VASOSPASM ON CEREBRAL BLOOD-FLOW (CBF) FOLLOWING SUBARACHNOID HEMORRHAGE (SAH)
    PITTS, LH
    MACPHERSON, P
    WYPER, DJ
    JENNETT, WB
    BLAIR, I
    COOK, M
    STROKE, 1979, 10 (01) : 98 - 98
  • [8] Antivasospastic effect and synergistic induction of HO-1 in cerebral vasospasm following SAH
    Tsunoda, H
    Tanaka, T
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2004, 94 : 104P - 104P
  • [9] Silent cerebral infarction due to vasospasm after SAH
    Claassen, J
    Mayer, SA
    Kreiter, KT
    Bates, JE
    Ostapkovich, N
    Mednick, AS
    Connolly, ES
    Carhuapoma, JR
    STROKE, 2001, 32 (01) : 356 - 356
  • [10] Current Management and Treatment of Cerebral Vasospasm Complicating SAH
    Kuehn, Anna Luisa
    Balami, Joyce Saleh
    Grunwald, Iris Quasar
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2013, 12 (02) : 233 - 241
12345